Temporal inhibition of ADAM17 in fibroblasts reduces stiffness and promotes vascularization following myocardial infarction
Cardiovascular Research · 24.02.2026 · 122 (1) · 112-131
DOI: 10.1093/cvr/cvaf256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 12.01.2026. Verfasst von Yingxi Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: ADAM17 Protein, Myocardial Infarction, Myocardium, Myofibroblasts. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, CIHR, Heart and Stroke Foundation.
Abstract (Originalsprache)
Aims
Myocardial infarction (MI) triggers a complex remodeling that, if uncontrolled, leads to heart failure. Increased levels of ADAM17 (disintegrin and metalloproteinase-17) in ischemic injury has been reported, but its direct role in scar formation and subsequent recovery from MI has not been identified. We investigated the role of ADAM17 in the function of homeostatic fibroblasts (FBs) vs. activated myofibroblasts (myoFBs) in scar formation, and recovery following MI. Methods and Results Human myocardial specimens showed upregulated ADAM17 in the infarct tissue, colocalized to myofibroblasts. We generated two inducible genetic mouse models with Adam17 knockdown in FBs (Adam17FB−KD) or myoFB (Adam17myoFB−KD) and subjected them to MI. Loss of ADAM17 in FBs impaired infarct formation and increased mortality due to left ventricular (LV) rupture in males and females. In contrast, ADAM17 loss in myoFBs limited infarct expansion, LV dilation and dysfunction up to 4-wks post-MI. Macrophage infiltration was suppressed in both genotypes. Ex vivo and in vitro experiments revealed that loss of ADAM17 in myoFB resulted in scar tissue with reduced stiffness due to suppressed activation of epidermal growth factor receptor and the Yes-associated protein (YAP) pathway. This promoted VEGFR signaling, endothelial cell (EC) proliferation, and vascularization in the infarcted myocardium, limiting infarct expansion. RNAseq analyses showed drastic changes in extracellular matrix (ECM) genes in Adam17KD FB and myoFBs in hypoxia. In vitro co-culture of myoFB and ECs confirmed that the ECM deposited by Adam17-deficient myoFB promotes EC proliferation and sprouting. Pharmacological inhibition of ADAM17 before MI was ineffective, but short-term ADAM17 inhibition after MI (targeting the myoFBs), limited infarct expansion, LV dilation and dysfunction up to 4-weeks post-MI.
Conclusion
Short-term inhibition of ADAM17 after MI optimizes the compliance of the infarct tissue, promoting vascularization, limiting infarct expansion, preventing long-term adverse LV remodeling, dysfunction, and heart failure. Targeting the homeostatic FB vs. myoFB also highlights the critical timing of ADAM17 inhibition as its presence is essential for the initial healing of the infarcted heart, but inhibition of its persistent upregulation reduces scar stiffness and improves the outcome post-MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
- Division of Cardiology, Department of Medicine, Faculty of Medicine and Dentistry, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada.
- Department of Mechanical Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB, Canada.
- Department of Immunology, University of Toronto, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
- Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, Hawaii, USA.
- Department of Biomedical Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB, Canada.
ORCID-Profile: Slava Epelman, Zamaneh Kassiri
Förderung
- NHLBI NIH HHS
- CIHR
- Heart and Stroke Foundation
- Canadian Institute for Health Research
- NIH
Zitieren
APA
Li, Y., Al Rimon, R., Wang, F., Li, H., Epelman, S., Tallquist, M. D., Westover, L., Oudit, G. Y., & Kassiri, Z. (2026). Temporal inhibition of ADAM17 in fibroblasts reduces stiffness and promotes vascularization following myocardial infarction. Cardiovascular Research, 122(1), 112-131. https://doi.org/10.1093/cvr/cvaf256
Vancouver
Li Y, Al Rimon R, Wang F, Li H, Epelman S, Tallquist MD, et al. Temporal inhibition of ADAM17 in fibroblasts reduces stiffness and promotes vascularization following myocardial infarction. Cardiovascular Research. 2026;122(1):112-131. doi:10.1093/cvr/cvaf256
BibTeX
@article{Li2026,
author = {Li, Yingxi and Al Rimon, Razoan and Wang, Faqi and Li, Haoyang and Epelman, Slava and Tallquist, Michelle D and Westover, Lindsey and Oudit, Gavin Y and Kassiri, Zamaneh},
title = {Temporal inhibition of ADAM17 in fibroblasts reduces stiffness and promotes vascularization following myocardial infarction},
journal = {Cardiovascular Research},
year = {2026},
volume = {122},
number = {1},
pages = {112--131},
doi = {10.1093/cvr/cvaf256}
}
EUVIMED